Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 Kinases by AT9283 In Children and Adolescents with Leukaemia

Jennifer E Podesta, Melanie J Griffin, Richard Sugar, Matthew S Squires, Alan Boddy, Spiros Linardopoulos, Andrew DJ Pearson, Andrew S Moore

Blood (2010) 116 (21): 1818.

https://doi.org/10.1182/blood.V116.21.1818.1818

Published: 2010

Journal Articles

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Xiaobing Liu, BS, Daniel Oscar Persky, MD, Thomas P. Miller, MD, Matthew S Squires, PhD, Wenqing Qi, PhD

Blood (2010) 116 (21): 3930.

https://doi.org/10.1182/blood.V116.21.3930.3930

Published: 2010

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Loredana Santo, MD, Teru Hideshima, MD, PhD, Diana Cirstea, MD, Madhavi L Bandi, PhD, Erik A Nelson, PhD, Hiroshi Ikeda, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Gullu Gorgun, PhD, Naoya Mimura, MD, Claire Fabre, MD, Yiguo Hu, PhD, Dharminder Chauhan, PhD, Matthew S Squires, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2994.

https://doi.org/10.1182/blood.V116.21.2994.2994

Published: 2010

Journal Articles

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells

Ruriko Tanaka, Matthew S. Squires, Shinya Kimura, Asumi Yokota, Rina Nagao, Takahiro Yamauchi, Miki Takeuchi, Hisayuki Yao, Matthias Reule, Tomoko Smyth, John F. Lyons, Neil T. Thompson, Eishi Ashihara, Oliver G. Ottmann, Taira Maekawa

Blood (2010) 116 (12): 2089–2095.

https://doi.org/10.1182/blood-2009-03-211466

Published: 2010

Includes: Supplemental data

Journal Articles

AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells.

Shamim Lotfi, MS, Aarthi Jayanthan, BS, Victor A. Lewis, MD, Greg Guilcher, MD, Matthew S Squires, PhD, Todd Cooper, DO, Aru Narendran, MD., Ph.D

Blood (2009) 114 (22): 3078.

https://doi.org/10.1182/blood.V114.22.3078.3078

Published: 2009

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.

Loredana Santo, M.D., Teru Hideshima, MD., Ph.D., Erik A. Nelson, Ph.D, Diana Cirstea, MD, Madhavi Bandi, Ph.D, Hiroshi Ikeda, MD, PhD, Gullu Gorgun, PhD, Sonia Vallet, MD., Samantha Pozzi, MD, Giulia Perrone, MD, Kishan Patel, Yiguo Hu, Ph.D, Matthew S Squires, Murray Yule, Elisabetta Calabrese, MD., Dharminder Chauhan, Ph.D, Nikhil C. Munshi, Kenneth C. Anderson, MD, Noopur Raje, MD.

Blood (2009) 114 (22): 3833.

https://doi.org/10.1182/blood.V114.22.3833.3833

Published: 2009

Journal Articles

The Activity of AT9283 in Acute Myeloid Leukemia in Vitro and in the Clinic Is Karyotype Dependent.

John F Lyons, PhD, Matthew S Squires, John Goodall, Murray Yule, Farhad Ravandi, MD, James Foran, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4159.

https://doi.org/10.1182/blood.V114.22.4159.4159

Published: 2009

Journal Articles

AT7519, a Potent Multi-Targeted CDK Inhibitor, Is Active in CLL Patient Samples Independent of Stage

Vicky Lock, Laurence Cooke, Murray Yule, Neil T Thompson, K. Della Croce, John F Lyons, Matthew S Squires, Daruka Mahadevan

Blood (2008) 112 (11): 3161.

https://doi.org/10.1182/blood.V112.11.3161.3161

Published: 2008

Journal Articles

Outcome of Aurora Kinase Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways.

John Goodall, Matthew S Squires, Vicky Lock, Farhad Ravandi, MBBS, Hagop M Kantarjian, James Foran, MD, Neil T Thompson, John F Lyons

Blood (2008) 112 (11): 1613.

https://doi.org/10.1182/blood.V112.11.1613.1613

Published: 2008

Journal Articles

AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β

Loredana Santo, MD, Sonia Vallet, M.D., Teru Hideshima, M.D., Ph.D., Diana Cirstea, MD, Samantha Pozzi, MD, Nileshwari Vaghela, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, Gullu Gorgun, PhD, Giulia Perrone, MD, Elisabetta Calabrese, MD, Matthew S Squires, Marco Ladetto, MD, Nikhil C. Munshi, MD, Mario Boccadoro, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2008) 112 (11): 251.

https://doi.org/10.1182/blood.V112.11.251.251

Published: 2008

Journal Articles

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

Ruriko Tanaka, MMSc, Matthew S Squires, PhD, Shinya Kimura, MD, PhD, Asumi Yokota, MMSc, Kirsty Mallett, PhD, Tomoko Smyth, PhD, Neil T Thompson, PhD, Rina Nagao, Takahiro Yamauchi, MD, Takashi Ushiki, MD, John F Lyons, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 1104.

https://doi.org/10.1182/blood.V112.11.1104.1104

Published: 2008

Journal Articles

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

Matthew S. Squires, PhD, Ruth E. Feltell, BSc, Victoria Lock, Donna M. Smith, PhD, Jon E. Lewis, Jacqueline Higgins, Murray Yule, MD, Neil T. Thompson, PhD, Laurence Cooke, Kimiko D. Croce, Wenqing Qi, John F. Lyons, PhD, Daruka Mahadevan

Blood (2007) 110 (11): 3127.

https://doi.org/10.1182/blood.V110.11.3127.3127

Published: 2007

Journal Articles

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Matthew S. Squires, PhD, Jayne E. Curry, Mark A. Dawson, Mike A. Scott, Kelly Barber, Matthias Reule, Tomoko Smyth, Nicola Wallis, Murray Yule, Neil T. Thompson, John F. Lyons, Anthony R. Green

Blood (2007) 110 (11): 3537.

https://doi.org/10.1182/blood.V110.11.3537.3537

Published: 2007

NARROW

Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 Kinases by AT9283 In Children and Adolescents with Leukaemia

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells

AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells.

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.

The Activity of AT9283 in Acute Myeloid Leukemia in Vitro and in the Clinic Is Karyotype Dependent.

AT7519, a Potent Multi-Targeted CDK Inhibitor, Is Active in CLL Patient Samples Independent of Stage

Outcome of Aurora Kinase Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways.

AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only